Full Press Release Details
NEW BRUNSWICK, N.J. , May 17, 2017 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders of Johnson & Johnson (NYSE: JNJ ) and its Janssen Pharmaceutical Companies will announce plans to launch or file for regulatory approval more than 10 new products with blockbuster potential between 2017 and 2021, as well as 50-plus line extensions of existing and new medicines that will bring the company's transformational medicines to an even broader patient population. The company will also share its plans to continue driving sustainable growth by leveraging its strong portfolio of core blockbuster products, the industry-leading productivity of its innovation model, and the pending acquisition of Swiss-based biotech company Actelion.
"With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world," said Alex Gorsky , Chairman and Chief Executive Officer. "Our pharmaceutical business will continue to be a significant driver of innovation and growth for Johnson & Johnson. With our proven global commercial capabilities and robust pipeline, we are well-positioned to continue delivering strong, long-term, sustainable growth."
An industry leader in research productivity, Janssen has received US FDA approval for 11 new molecular entities (NMEs) since 2011. With a portfolio focused on five core therapeutic areas – Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism, and Oncology – the Pharmaceutical segment of Johnson & Johnson is delivering transformational new medicines for unmet medical needs worldwide, and expects to add a sixth therapeutic area in Pulmonary Arterial Hypertension upon the completion of the acquisition of Actelion, which is expected to close by the end of the second quarter.
In 2016, the company filed two NMEs that it anticipates will be approved and launched later this year:
Additional late-stage blockbuster products 1 projected to file for regulatory approvals between 2017 and 2021, include:
About Today's Meeting
The meeting will be webcast starting at 8:30 a.m. EDT today and can be accessed along with full copies of the presentations and speaker biographies via the Johnson & Johnson Investor Relations website: www.investor.jnj.com . A replay and podcast will be available shortly after the live webcast. A live Twitter feed for today's meeting is accessible via #PBR17JNJ.
Users of the Johnson & Johnson Investor Relations mobile app for the iPad® and iPhone® mobile digital devices can also access the event. This free app is available in the iTunes® store and includes stock information, news releases, company information, webcasts, SEC filings, the company's pharmaceutical product pipeline and Annual Reports, among other information.
About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 130,800 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
iPad, iPhone and iTunes are trademarks of Apple Inc.
1 Many of these products are being developed in collaboration with strategic partners or are licensed from other companies; see webcast presentation for more information.
SOURCE Johnson & Johnson